About The Study: The results of this study suggest a benefit associated with the availability of effective therapies for melanoma in the past decade and further suggest that the use of new pharmacological therapies is associated with a decrease in the melanoma mortality rate in the U.S. population. These data are very encouraging and support the continued development of such therapies. Additionally, the accessibility of these treatments and the associated health care costs needs to be addressed.
Authors: Navkirat Kahlon, M.D., M.P.H., of the University of Toledo College of Medicine and Life Sciences in Toledo, Ohio, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.45269)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.45269?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=120622
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Journal
JAMA Network Open